Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2 Amplified Breast Cancer”

51 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 51 results

Testing effectiveness (Phase 2)Study completedNCT04366713
What this trial is testing

Characterize Colon Pathology in Patients With HER2 Amplified Breast Cancer Treated With Neratinib

Who this might be right for
HER2 Amplified Breast Cancer
Puma Biotechnology, Inc. 6
Post-approval studies (Phase 4)Looking for participantsNCT07195344
What this trial is testing

Study Aiming to Compare the Plasma Exposure of the Payload (Free-DXd) in Patients Treated by T-DXd for Locally Advanced or Metastatic Breast Cancer According to Their BMI.

Who this might be right for
Locally Advanced or Metastatic Breast Cancers
Institut Claudius Regaud 210
Testing effectiveness (Phase 2)Looking for participantsNCT06840483
What this trial is testing

Study of Zelenectide Pevedotin in Participants With Advanced Breast Cancer

Who this might be right for
Breast Cancer
BicycleTx Limited 66
Not applicableStudy completedNCT00535509
What this trial is testing

Phase II Trial of Neoadjuvant[FEC100]/Cisplatin-Docetaxel ± Trastuzumab in Women With Over Expressed or Amplified Her2/Neu With Locally Advanced Breast Cancer

Who this might be right for
Breast Cancer
King Faisal Specialist Hospital & Research Center 285
Testing effectiveness (Phase 2)Study completedNCT01050322
What this trial is testing

Safety Study in Subjects With Metastatic Breast Cancer Who Progressed After Taxanes Treatment.

Who this might be right for
BRMS1Performance Status Zero to Two for Beginning the StudyPatient With a Maximum of One Chemotherapy+1 more
Latin American Cooperative Oncology Group 142
Testing effectiveness (Phase 2)Looking for participantsNCT06726148
What this trial is testing

Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

Who this might be right for
Advanced HR+/HER2- Breast CancerAdvanced CCNE1-amplified Solid Tumors
Novartis Pharmaceuticals 280
Not applicableStudy completedNCT00097487
What this trial is testing

Patients With HER2 Gene Amplified Metastatic Breast Cancer Treated With First Line Herceptin and a Taxane

Who this might be right for
Breast CancerMetastases
Genentech, Inc. 1,000
Testing effectiveness (Phase 2)Study completedNCT01975142
What this trial is testing

Validity of HER2-amplified Circulating Tumor Cells to Select Metastatic Breast Cancer Considered HER2-negative for Trastuzumab-emtansine (T-DM1) Treatment.

Who this might be right for
Metastatic Breast Cancer, HER2 Negative Primary Tumor
Institut Curie 155
Testing effectiveness (Phase 2)Active Not RecruitingNCT03820141
What this trial is testing

Durvalumab with Trastuzumab and Pertuzumab in HER2-Enriched Breast Cancer

Who this might be right for
Breast Cancer
The Methodist Hospital Research Institute 39
Early research (Phase 1)Study completedNCT00911898
What this trial is testing

MM-111 in Patients With Advanced, Refractory Her2 Amplified, Heregulin Positive Cancers

Who this might be right for
Her2 Amplified Solid TumorsMetastatic Breast Cancer
Merrimack Pharmaceuticals 20
Testing effectiveness (Phase 2)Study completedNCT02005887
What this trial is testing

TRial on the Endocrine Activity of Neoadjuvant Degarelix

Who this might be right for
Breast Cancer Invasive Nos
ETOP IBCSG Partners Foundation 51
Testing effectiveness (Phase 2)Study completedNCT00482391
What this trial is testing

Doxorubicin and Cyclophosphamide Followed by Paclitaxel, Trastuzumab, and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer

Who this might be right for
Breast Cancer
Memorial Sloan Kettering Cancer Center 95
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07193394
What this trial is testing

Tucatinib and Trastuzumab in HER3-mutant and HER2-not Amplified Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer ( HER2 Negative)Unresectable Breast Cancer
Institut Curie 20
Early research (Phase 1)Study completedNCT01097460
What this trial is testing

MM-111 in Combination With Herceptin in Patients With Advanced Her2 Amplified, Heregulin Positive Breast Cancer

Who this might be right for
Breast Neoplasms
Merrimack Pharmaceuticals 16
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07220135
What this trial is testing

Trial of Neoadjuvant THP vs TCHP for HER2-Amplified/Positive Breast Cancer

Who this might be right for
Breast Cancer
University of Kansas Medical Center 100
Testing effectiveness (Phase 2)Ended earlyNCT00820924
What this trial is testing

Study of Lapatinib in Breast Cancer Patients With HER-2 Non-amplified Primary Tumors and HER-2 Positive or EGFR Positive Circulating Tumor Cells

Who this might be right for
Neoplasms, Breast
GlaxoSmithKline 23
Testing effectiveness (Phase 2)Study completedNCT01111825
What this trial is testing

Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer

Who this might be right for
Breast Cancer
Puma Biotechnology, Inc. 99
Early research (Phase 1)Study completedNCT00031681
What this trial is testing

7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)

Who this might be right for
Advanced Adult Primary Liver CancerCarcinoma of the AppendixEstrogen Receptor-negative Breast Cancer+85 more
National Cancer Institute (NCI) 41
Testing effectiveness (Phase 2)Study completedNCT02091960
What this trial is testing

Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) Metastatic or Locally Advanced Breast Cancer

Who this might be right for
HER2 AmplifiedAdvanced Breast CancerHuman Epidermal Growth Factor Receptor 2 (HER2)
Astellas Pharma Global Development, Inc. 103
Early research (Phase 1)Study completedNCT03238196
What this trial is testing

Fulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Vanderbilt-Ingram Cancer Center 35
Load More Results